Annamycin MIRACLE Part A Unblinding: Pivotal Signal or Premature Confidence in R/R AML?

Moleculin CEO Discusses Positive Preliminary MIRACLE Trial Results

Moleculin Biotech's CEO, Walter Klemp, participated in a Virtual Investor "What This Means" segment to discuss positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial. This trial evaluates Annamycin, in combination with cytarabine (AnnAraC), for relapsed or refractory acute myeloid leukemia (R/R AML). Klemp highlighted early efficacy trends observed across both Annamycin treatment arms and discussed the commercial opportunity, including insights from recent market research on the potential addressable market for Annamycin if approved.

• Moleculin Biotech's CEO, Walter Klemp, presented positive preliminary unblinded efficacy results from the initial 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial. The discussion, part of a Virtual Investor segment, focused on early efficacy trends observed across both Annamycin treatment arms for relapsed or refractory acute myeloid leukemia (R/R AML).
• The MIRACLE trial (MB-108) is a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 study. It evaluates Annamycin in combination with cytarabine (AnnAraC) for R/R AML. Annamycin, the company's lead program, is an anthracycline designed to overcome multidrug resistance and avoid cardiotoxicity, a common issue with existing treatments.
• Following a successful Phase 1B/2 study (MB-106) and input from the FDA, Moleculin believes the development pathway for Annamycin in AML is substantially de-risked. The company also conducted market research, which provided insights into the potential addressable market for Annamycin, underscoring its commercial opportunity if approved.
• Beyond Annamycin, Moleculin is advancing other therapeutic candidates. These include WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic, and other cancers, and WP1122, an antimetabolite for pathogenic viruses and certain cancer indications, demonstrating a diverse pipeline addressing hard-to-treat conditions.

Addressing the Challenges in Relapsed/Refractory AML Treatment

Relapsed/refractory (R/R) AML remains one of the most therapeutically challenging malignancies, characterized by poor long-term outcomes across most patient subgroups. High relapse rates, intrinsic and acquired resistance mechanisms, and the biological heterogeneity of the disease collectively limit the effectiveness of current standard-of-care approaches.

• High relapse rates and poor long-term survival persist even after achievement of complete remission with intensive induction therapy, with outcomes particularly dismal in patients over 60 years of age, who frequently present with unfavorable cytogenetics, P-glycoprotein (P-gp) expression, and functional drug efflux.

• Intrinsic chemotherapy resistance affects the majority of AML patients at initial diagnosis, often driven by MDR-1 gene expression encoding P-gp-mediated drug efflux; at relapse, additional transporter proteins — including lung-resistance protein (LRP) and MDR-associated protein (MRP) — are expressed at higher frequency, further compounding therapeutic failure. Patients with P-gp-positive secondary AML and unfavorable cytogenetics have reported complete remission rates as low as 12%.

• TP53-mutated AML presents a distinct and unresolved clinical challenge: while hypomethylating agent/venetoclax-based regimens yield improved initial responses, remissions are generally short-lived and overall survival remains poor, underscoring the urgent need for more effective therapeutic strategies in this molecular subset.

• Hypomethylating agents (HMAs), including azacitidine and decitabine, offer therapeutic access for patients ineligible for intensive chemotherapy, but long-term outcomes remain largely unsatisfactory, with relapse and therapeutic resistance continuing to limit their utility even in combination with venetoclax.

• Barriers to allogeneic hematopoietic cell transplantation (allo-HCT) — the only potentially curative option for many R/R AML patients — include persistent or relapsed disease at the time of transplant eligibility assessment, as well as patient-related factors such as fitness and preference, restricting its applicability to a limited proportion of the R/R population.

• Immunotherapeutic approaches remain constrained by the immunosuppressive tumor microenvironment (TME) and a scarcity of validated, leukemia-specific immunotherapeutic targets, limiting the clinical translation of immune-based strategies that have shown success in other hematologic malignancies.

Preliminary Efficacy from the MIRACLE Trial in R/R AML

Recent clinical investigations in relapsed/refractory (R/R) AML have evaluated a range of targeted and combination strategies, with data emerging across IDH inhibition, BCL-2–based regimens, FLT3-directed therapy, and novel epigenetic combinations. The studies below represent key recent evidence informing treatment decision-making in this high-unmet-need setting.

Positioning Annamycin in the R/R AML Treatment Landscape

The R/R AML treatment landscape encompasses a heterogeneous range of approaches — from hypomethylating agent (HMA)-based regimens to targeted agents and salvage chemotherapy — with outcomes varying substantially by regimen, patient fitness, and molecular profile. Published data consistently demonstrate that no single standard-of-care regimen dominates in the R/R setting, underscoring the persistent unmet need for more efficacious therapies. The comparisons below synthesize efficacy and safety data across key regimens evaluated in clinical studies.